Documentation Centre

 

 

  of 1511 Next page

Go to page: of

Screenshot Date Categories Title Author Format
As a clinician and a scientist, could you comment on the successes and surprises of atherosclerosis research? December 05, 2018 As a clinician and a scientist, could you comment on the successes and surprises of atherosclerosis research? Peter Libby, MD, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA, USA Expert Opinions
Video 3:55 min.
(22 MB)
Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans. Am J Physiol Endocrinol Metab. 2018;315:E126-E132 November 30, 2018 Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans. Am J Physiol Endocrinol Metab. 2018;315:E126-E132 Beysen C, Ruddy M, Stoch A, Mixson L, Rosko K, Riiff T, Turner SM, Hellerstein MK, Murphy EJ. Key Publications
Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care. 2018;41:1732-1739 November 28, 2018 Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care. 2018;41:1732-1739 Luukkonen PK, Sädevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, Lallukka S, Pelloux V, Gaggini M, Jian C, Hakkarainen A, Lundbom N, Gylling H, Salonen A, Orešič M, Hyötyläinen T, Orho-Melander M, Rissanen A, Gastaldelli A, Clément K, Hodson L, Yki-Järv Key Publications
PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle? Eur Heart J. 2018;39:2586-2588 November 27, 2018 PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle? Eur Heart J. 2018;39:2586-2588 Pirillo A, Catapano AL Key Publications
Lipoprotein(a): the perpetual supporting actor. Eur Heart J. 2018;39:2597-2599 November 27, 2018 Lipoprotein(a): the perpetual supporting actor. Eur Heart J. 2018;39:2597-2599 Gencer B, Mach F Key Publications
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39:2589-2596 November 27, 2018 Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39:2589-2596 Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT, Boekholdt SM, Nordestgaard BG, Stroes ESG Key Publications
Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur Heart J. 2018;39:2562-2573 November 26, 2018 Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur Heart J. 2018;39:2562-2573 Ruuth M, Nguyen SD, Vihervaara T, Hilvo M, Laajala TD, Kondadi PK, Gisterå A, Lähteenmäki H, Kittilä T, Huusko J, Uusitupa M et al. Key Publications
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018;39:2577-2585 November 26, 2018 Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018;39:2577-2585 Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR Key Publications
Pathological phenotypes of LDL particles. Eur Heart J. 2018;39:2574-2576 November 26, 2018 Pathological phenotypes of LDL particles. Eur Heart J. 2018;39:2574-2576 Laufs U, Weingärtner O Key Publications
'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. Eur Heart J. 2018;39:2546-2550 November 26, 2018 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. Eur Heart J. 2018;39:2546-2550 Annemans L, Packard CJ, Briggs A, Ray KK Key Publications

  of 1511 Next page

Go to page: of